AffiliationDepartment of Medical Oncology, St James' University Hospital, Leeds, UK. email@example.com
MetadataShow full item record
AbstractEpithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Increased understanding of the pathways and molecules involved in angiogenesis has allowed the identification of a number of targets for antiangiogenic therapies and the development of a variety of antiangiogenic drugs. There is now significant preclinical evidence, and a growing body of clinical data, demonstrating promising results with antiangiogenic drugs in the treatment of EOC. Single-agent VEGF inhibitor response rates in pretreated patients of between 15 and 20% have been reported, with much higher response rates when used in combination with chemotherapeutic agents. These benefits, however, must be balanced with the toxicities associated with these drugs, particularly the more serious ones, such as gastrointestinal perforation. The results of ongoing and future randomized clinical trials will confirm if, and how, antiangiogenic therapies should be integrated into the routine management of EOC. However, critical issues, such as the relative importance of combination remission induction regimens and maintenance therapy, remain poorly defined.
CitationDevelopment of antiangiogenic agents for ovarian cancer. 2008, 8 (1):21-32 Expert Rev Anticancer Ther
JournalExpert Review of Anticancer Therapy
- Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
- Authors: Teoh D, Secord AA
- Issue date: 2012 Mar
- Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
- Authors: Al Wadi K, Ghatage P
- Issue date: 2016
- Antiangiogenic therapies in epithelial ovarian cancer.
- Authors: Teoh DG, Secord AA
- Issue date: 2011 Jan
- The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
- Authors: Secord AA, Nixon AB, Hurwitz HI
- Issue date: 2014 Nov
- Angiogenesis inhibitors for the treatment of ovarian cancer.
- Authors: Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J
- Issue date: 2011 Sep 7